Floatz logo

Tislelizumab

KRAS Mutation-Related Tumors

Shanghai Chest Hospitalmonoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the KRAS Mutation-Related Tumors cohort.

Asset / SponsorPhaseRating
Binimetinib
Abramson Cancer Center at Penn Medicine
Phase 2B
Hydroxychloroquine
Abramson Cancer Center at Penn Medicine
Phase 2B
Irinotecan
Institut de Recherches Internationales Servier
Phase 1/2CCC
FLUOROURACILUM
Institut de Recherches Internationales Servier
Phase 1/2CCC
Calcium folinate pentahydrate
Institut de Recherches Internationales Servier
Phase 1/2CCC

View all 25 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Hepatic Metastasis of Pancreatic CancerDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →